These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25281027)

  • 21. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
    Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
    Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.
    Sarrió D; Moreno-Bueno G; Sánchez-Estévez C; Bañón-Rodríguez I; Hernández-Cortés G; Hardisson D; Palacios J
    Hum Pathol; 2006 Aug; 37(8):1042-9. PubMed ID: 16867867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma.
    Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2012 Aug; 32(8):3091-5. PubMed ID: 22843878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
    Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
    Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Oda K; Hamanishi J; Matsuo K; Hasegawa K
    Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma.
    Liu S; Ma X; Ai Q; Huang Q; Shi T; Zhu M; Wang B; Zhang X
    Urol Oncol; 2013 Aug; 31(6):938-48. PubMed ID: 21993533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.
    Lau MT; Leung PC
    Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.
    Morikawa A; Hayashi T; Kobayashi M; Kato Y; Shirahige K; Itoh T; Urashima M; Okamoto A; Akiyama T
    Oncol Rep; 2018 Jul; 40(1):309-318. PubMed ID: 29749539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
    Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
    J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
    Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
    BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
    Carden CP; Stewart A; Thavasu P; Kipps E; Pope L; Crespo M; Miranda S; Attard G; Garrett MD; Clarke PA; Workman P; de Bono JS; Gore M; Kaye SB; Banerji U
    Mol Cancer Ther; 2012 Jul; 11(7):1609-17. PubMed ID: 22556379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.
    Zhai Y; Kuick R; Tipton C; Wu R; Sessine M; Wang Z; Baker SJ; Fearon ER; Cho KR
    J Pathol; 2016 Jan; 238(1):21-30. PubMed ID: 26279473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
    Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression.
    Peiró G; Diebold J; Löhrs U
    Am J Clin Pathol; 2002 Dec; 118(6):922-9. PubMed ID: 12472286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.
    Rogers HA; Mayne C; Chapman RJ; Kilday JP; Coyle B; Grundy RG
    Clin Cancer Res; 2013 Dec; 19(23):6450-60. PubMed ID: 24077346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
    Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
    Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.